Your guide to IBD novel treatments and assessment tools
UEG Week 2018 saw a host of insights and symposia surrounding the assessment and treatment of Irritable Bowl Disease (IBD). Our expert faculty explored these recent advances and looked at the potential impact that biosimilars could have. Below is a round up of some of the key findings for you to explore for free at your own convenience.
New assessment tools in IBD may change your clinical practice. In this educational symposium 'Current IBD Management Strategies: Role of disease assessment' our expert faculty discuss assessment tools including the IBD index, and more. Watch the symposium here
Bitesize expert opinion
Hear from Dr Krisztina Gecse, distilling best practice use of currently available assessment tools, the role that biomarkers can play, and the potential of biosimilars to alter the current treatment paradigm. Watch the interviews
The view from UEG Week 2018
Review the report and analysis from a packed UEGW Vienna as we present daily reviews compiled by our team of scientific writers. Read the reports here
Related news and insights
Biora Therapeutics, Inc. announced topline results from its recently completed study PM 602: A Scintigraphic Study to Evaluate the Localization and Delivery Function of a Drug Delivery System Capsule (DDS) in Subjects with Ulcerative Colitis in a Fasted State
In Eli Lilly and Company's pivotal, Phase III LUCENT-2 study, patients with ulcerative colitis (UC) who responded to mirikizumab at 12 weeks achieved and maintained statistically superior and clinically meaningful improvements at one year compared to placebo across the primary endpoint of clinical remission and all key secondary endpoints, including bowel urgency severity, using a novel, patient-reported outcome measure.
Pfizer Inc. announced detailed results from two pivotal studies that make up the ELEVATE UC Phase III registrational program evaluating etrasimod, a once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately-to-severely active ulcerative colitis (UC).